Welcome to our dedicated page for Gohealth SEC filings (Ticker: GOCO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The GoHealth, Inc. (NASDAQ: GOCO) SEC filings page on Stock Titan brings together the company’s regulatory disclosures from the U.S. Securities and Exchange Commission, along with AI-powered tools to help interpret them. As a health insurance marketplace and Medicare-focused digital health company, GoHealth uses its filings to report financial results, capital structure changes, governance updates, and key operating metrics.
Core documents for GOCO include annual reports on Form 10-K and quarterly reports on Form 10-Q, where the company discusses its Medicare-focused marketplace model, non-GAAP measures such as EBITDA and Adjusted EBITDA, and operating metrics like Submissions, Sales per Submission, Direct Operating Cost of Submission, and Direct Operating Cost per Submission. These filings also contain sections such as “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” which elaborate on the environment in which GoHealth operates.
GoHealth’s current reports on Form 8-K provide timely detail on material events. Recent 8-K filings describe the announcement of quarterly results, the entry into a superpriority senior secured term loan facility, amendments to the existing credit agreement, the issuance of Class A common stock to lenders, and changes in the composition of the board of directors, including the creation of a Transformation Committee. Other 8-Ks report annual meeting voting results and director appointments or resignations.
On this page, Stock Titan’s AI features summarize lengthy filings so users can quickly see what changed in each document, such as new financing terms, covenant adjustments, or governance provisions. Real-time updates from EDGAR ensure that newly filed 10-Ks, 10-Qs, and 8-Ks for GOCO appear promptly, while AI-generated highlights help explain complex credit agreement amendments, liquidity covenants, and board-level decisions.
For those examining GoHealth’s regulatory history, this filings page offers structured access to its SEC reports, including details on financial performance, capital structure, and corporate governance, supported by automated summaries that make dense legal and financial language easier to understand.
William L. Transier filed an Initial Form 3 reporting his relationship to GoHealth, Inc. (GOCO) as a director. The event date is 08/06/2025. The filing states that no securities are beneficially owned by the reporting person and includes Exhibit 24 (Power of Attorney). The form lists a Chicago address for the reporting person and is signed on behalf of Transier by an attorney-in-fact on 08/08/2025.
On 6 Aug 2025, GoHealth (GOCO) executed a series of financing and governance actions aimed at improving near-term liquidity and extending maturities.
- $115 m super-priority term loan: $80 m in new money ($40 m funded now; $40 m delayed-draw before Dec-25) plus $35 m roll-up of existing revolver. Rate: Term SOFR + 5.50 % (3 % floor) or ABR + 4.50 % (4 % floor) plus a cash MOIC premium of up to 2.0×. Maturity: 5 Aug 2029. First-lien on substantially all assets and senior to the existing credit facility.
- Covenants: Weekly minimum liquidity starts at $5 m (Oct-25) and rises to $30 m (Sep-26). Borrower barred from prepaying legacy Class A loans until super-priority debt is fully repaid.
- Amendment No. 14: Terminates unused revolver commitments, extends remaining Class A revolver maturity to 2029, allows part PIK interest (Adj. SOFR + 8 %) and waives term-loan amortization until 31 Dec 2026. Leverage and asset coverage covenants removed.
- Equity issuance: Lenders received 4,766,219 Class A shares (~19.99 % of pre-transaction shares) in a private placement.
- Board changes: Three directors appointed (Timothy R. Pohl, Alan J. Carr, William L. Transier); three directors resigned. A new Transformation Committee will evaluate strategic alternatives.
The package provides fresh capital and maturity relief but at high cost and with substantial dilution and restrictive covenants.
GoHealth (Nasdaq: GOCO) filed an 8-K disclosing the results of its 2025 Annual Meeting of Stockholders held on June 18, 2025.
Shareholders elected three Class II directors—Brandon M. Cruz (17,218,021 FOR), Alan Wheatley (17,932,740 FOR) and Abhiraj R. Modi (17,619,537 FOR)—to serve until the 2028 meeting. Ernst & Young LLP was ratified as independent auditor with 21,544,738 FOR and only 557,922 AGAINST. The non-binding say-on-pay resolution passed (17,026,293 FOR; 992,227 AGAINST), and shareholders approved an amendment to the 2020 Incentive Award Plan (16,755,619 FOR; 1,287,341 AGAINST).
No financial performance metrics, strategic updates, or other material events were included in the filing.